Pediatric Hypertension Clinical Trial
Official title:
An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics of a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension
The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of TAK-536 in pediatric patients aged 6 to less than 16 years with hypertension.
This is an open-label, phase 3, multicenter study to evaluate the pharmacokinetics and
safety of a single oral dose of TAK-536 in pediatric patients aged 6 to less than 16 years
with hypertension.
The subjects will be admitted to hospital by the day before study drug administration, and a
single dose of TAK-536 will be administered: TAK-536 5 mg to subjects weighing less than 50
kg and TAK-536 10 mg to subjects weighing 50 kg or more.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00244634 -
Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age
|
Phase 3 | |
| Terminated |
NCT03783650 -
Boosting Primary Care Awareness and Treatment of Childhood Hypertension
|
N/A | |
| Completed |
NCT02791438 -
A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension
|
Phase 3 | |
| Completed |
NCT03461003 -
N-of-1 Trials In Children With Hypertension
|
Phase 4 |